Pulmonary diseases pose a major health problem worldwide with millions of affected individuals and dire economic impact.

Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...

A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...

The rise of infections caused by Mgen, C. auris, treatment-resistant E. coli, and more could become future public-health threats, experts say.

Advanced biotechnology repurposes two bacterial immune systems to correct large stretches of DNA. Human cells that have been edited with the new retron-based gene editing technology. Orange dots mark ...

Insmed shares fell by -1.9% during the day's morning session, and are now trading at a price of $138.35. Is it time to buy the dip? To better answer that question, it's essential to check if the ...

Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

A research effort led by scientists from the Keck School of Medicine at the University of Southern California (USC) has led to the development of more mature and complex lab-grown kidney progenitor ...

Nontuberculous Mycobacteria (NTM), especially Mycobacterium avium-intracellulare complex (MAC), has been considered responsible for human disease, especially in HIV patients. Nevertheless, it has been ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...